RecruitingRecruiting
Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma
NCT07067905 · Chinese PLA General Hospital
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
A prospective, open-label, phase 1 study. This clinical trial aims to evaluate the diagnostic value of 68Ga-XT771, a CAIX/CAXII protein-specific probe, in PET/CT imaging for patients with clear cell renal cell carcinoma and glioblastoma. Safety, tolerability, and biodistribution characteristics of 68Ga-XT771 will also be assessed.
Eligibility criteria
Inclusion Criteria:
* 1\. signed the informed consent 2. ≥18 years old 3. Patients with glioblastoma or clear cell renal cell carcinoma
Exclusion Criteria:
* 1\. Known allergy to components of the investigational drug or its analogues 2. suspected to have a certain disease or condition that is not suitable for the study drug 3. Known pregnant or lactating women
Study design
Enrollment target: 15 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2025-06-27
Estimated completion: 2026-06-01
Last updated: 2025-07-16
Interventions
Drug: 68Ga-XT771
Primary outcomes
- • Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] (7 days following injection)
Sponsor
Chinese PLA General Hospital · other
With: Sinotau Pharmaceutical Group
Contacts & investigators
ContactRuimin Wang · contact · wrm@yeah.net · +8613501151740
All locations (1)
Chinese PLA General HospitalRecruiting
Beijing, China